己酸,2-丁基-2-乙基-,甲基酯 | 107655-65-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 己酸,2-丁基-2-乙基-,甲基酯
• 英文名称: 7,25-dihydroxycholesterol
• 英文别名: (3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
• CAS: 107655-65-2
• 化学式: C₂₇H₄₆O₃
• 分子量: 418.66
• InChiKey: BQMSKLCEWBSPPY-BXGICBJUSA-N

物化性质

• 沸点：
  548.5±35.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF<br/>[FR] AGENTS THÉRAPEUTIQUES MODIFIÉS ET COMPOSITIONS DE CEUX-CI
  申请人：CALIFORNIA INST BIOMEDICAL RES

  公开号：WO2015038938A1

  公开（公告）日：2015-03-19

  Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.

  提供了一种延长治疗剂半衰期的方法和组合物。可以将一个或多个延长半衰期的基团连接到治疗剂上，从而延长治疗剂的半衰期。含有一个或多个连接到治疗剂上的延长半衰期基团的改良治疗剂（mTAs）可用于治疗需要的患者的疾病或状况。
• GPR183 ANTAGONISTS FOR THE TREATMENT OF PAIN
  申请人：Saint Louis University

  公开号：US20210122750A1

  公开（公告）日：2021-04-29

  Disclosed herein are compositions and methods for treating neuropathic pain in a subject in need thereof. Compositions disclosed herein are GPR183 antagonists. The methods include administering to a subject in need thereof a therapeutically effective amount of a GPR183 antagonist.

  本文揭示了用于治疗需要神经病痛的主体的组合物和方法。本文揭示的组合物是GPR183拮抗剂。该方法包括向需要的主体投予治疗有效量的GPR183拮抗剂。
• [EN] CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS<br/>[FR] CONJUGUÉS POUR UNE RÉACTIVITÉ SÉLECTIVE À DES DIOLS VICINAUX
  申请人：PROTOMER TECH INC

  公开号：WO2021202802A1

  公开（公告）日：2021-10-07

  Embodiments of the present disclosure relate to sensors that can selectively bind to specific vicinal diols in the presence of other diols. These boronated vicinal diol-responsive sensor compounds can sense levels of specific vicinal diols and respond to these molecules in the body. In certain embodiments, the vicinal diol is a cis diol, for example, a hexose such as glucose. In certain embodiments the sensors are conjugated to a drug substance, and the sensors may change the biophysical characteristics, pharmacokinetics, and/or activity of the drug substance in response to the vicinal diol. The drug substance may be or include a polypeptide, such as an insulin, a human endocrine or incretin peptide, or an analogue thereof, and may contain one or more modified amino acids containing a vicinal diol-responsive sensor.

  本公开的实施例涉及传感器，该传感器可以在其他二醇存在的情况下选择性地结合特定的邻二醇。这些硼化邻二醇响应传感器化合物可以感知特定邻二醇的水平，并对这些分子在体内做出反应。在某些实施例中，邻二醇是顺式二醇，例如六糖，如葡萄糖。在某些实施例中，传感器与药物物质结合，传感器可以改变药物物质的生物物理特性，药代动力学和/或活性，以响应邻二醇。药物物质可以是或包括多肽，例如胰岛素，人类内分泌或肠促素肽或其类似物，并且可能包含一个或多个含有邻二醇响应传感器的修饰氨基酸。
• Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
  申请人：THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

  公开号：US10039809B2

  公开（公告）日：2018-08-07

  Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

  提供了延长治疗剂半衰期的方法和组合物。改性治疗剂（mTA）由治疗剂、主食和延长半衰期分子组成。本文公开的 mTA 可用于治疗有需要的受试者的疾病或病症。
• Compound and method for the treatment and diagnosis of neurodegenerative conditions
  申请人：SWANSEA UNIVERSITY

  公开号：US10226475B2

  公开（公告）日：2019-03-12

  A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3β,7α-dihydroxycholest-5-en-26-oic (3β,7α-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.

  一种选自胆烯酸或胆烯酸生物合成或代谢途径中酶的抑制剂的试剂，用于治疗神经退行性疾病。特别是，该试剂是一种特殊形式的胆甾烯酸，如 3β,7α-二羟基胆甾烯-5-烯-26-酸（3β,7α-diHCA），以前与神经组织或 CSF 无关。本发明还包括药物组合物、治疗或预防神经退行性疾病的方法以及诊断方法和新型生物标记物。